Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6952W HIGH $2.18
Volume
477.62 K
Value Traded
313.76 K
Short % Float
0.85%
-3.92%Week
-7.03%1 Month
-21.5%3 Month
-48.37%6 Month
-99.79%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
66.37 M
EPS (TTM)
-0.58
P/E Ratio
-
Ent. Value
25.72 M
Total Shares
86.27 M
Float Shares
78.95 M
Insiders
8.49%
Institutions
48.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
RNTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Rein Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rein Therapeutics, Inc.
105Total events
8Upcoming
24Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationLTI-03Presentation
Late-breaking poster presentation at ERS 2026 Congress
idiopathic pulmonary fibrosissource ↗
▲Fast Track DesignationLTI-03Designation
FDA grants Fast Track designation for LTI-03 in IPF
idiopathic pulmonary fibrosissource ↗
▲PublicationLTI-03Presentation
Publication of first-in-human LTI-03 data in Nature Communications
idiopathic pulmonary fibrosissource ↗
▲Enrollment MilestoneLTI-03Trial
Surpassed 25% enrollment milestone in Phase 2 RENEW trial
idiopathic pulmonary fibrosis (IPF)source ↗
▲PublicationLTI-03Presentation
Publication in Nature Communications of first-in-human study
idiopathic pulmonary fibrosis (IPF)source ↗
▲Enrollment MilestoneLTI-03Trial
Phase 2 RENEW trial now enrolling across all five countries (Germany joins)
idiopathic pulmonary fibrosissource ↗
◆Enrollment UpdateLTI-03Trial
16 patients enrolled to date in Phase 2 RENEW trial
idiopathic pulmonary fibrosissource ↗
▲First Patient DosedLTI-03Trial
First patient randomized in the United Kingdom
idiopathic pulmonary fibrosissource ↗
▼Equity OfferingCorporate
Closing of $57.5 million underwritten public offering of common stock, including full exercise of over-allotment option
▼Equity OfferingCorporate
Pricing of $50 million underwritten public offering of common stock at $1.00 per share
◆Enrollment UpdateLTI-03Trial
2 additional patients expected to be enrolled this week
idiopathic pulmonary fibrosissource ↗
▲Trial InitiationLTI-03Trial
Clinical trial sites active in US, Australia, Poland; UK and Germany expected to open
idiopathic pulmonary fibrosissource ↗
▲First Patient DosedLTI-03Trial
First patient dosed in Phase 2 trial of LTI-03 for IPF
idiopathic pulmonary fibrosissource ↗
▲IND ClearanceLTI-03IND
FDA clearance to resume Phase 2 program for LTI-03
idiopathic pulmonary fibrosissource ↗
▲Enrollment MilestoneLTI-03Trial
Enrollment initiated in March 2026
idiopathic pulmonary fibrosissource ↗
▲EU Orphan DesignationLTI-03Ex-US Regulatory
EMA orphan drug designation for LTI-03 in IPF
idiopathic pulmonary fibrosissource ↗
◆Topline ReadoutLTI-03Clinical Data
Topline interim data from RENEW Phase 2 trial expected
idiopathic pulmonary fibrosissource ↗
◆Enrollment UpdateLTI-03Trial
Resumption of patient recruitment expected in late 2025 or early 2026
idiopathic pulmonary fibrosissource ↗
▲Clinical Hold LiftedLTI-03IND
FDA lifts full clinical hold on Phase 2 trial of LTI-03 in IPF
idiopathic pulmonary fibrosissource ↗
●PreprintLTI-03Presentation
Preprint of LTI-03 clinical data released
idiopathic pulmonary fibrosissource ↗
▲PreprintLTI-03Presentation
Preprint posted on medRxiv describing clinical and translational findings from inhaled dose-escalation study of LTI-03 in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
▲Other Regulator MilestoneLTI-03Ex-US Regulatory
EMA authorization to initiate Phase 2 trial in Germany and Poland
idiopathic pulmonary fibrosissource ↗
▲PublicationLTI-03Presentation
Publication of translational data on LTI-03 in iScience
idiopathic pulmonary fibrosissource ↗
▲MHRA MilestoneLTI-03Ex-US Regulatory
MHRA regulatory approval to initiate Phase 2 RENEW trial
idiopathic pulmonary fibrosissource ↗
◆Oral PresentationLTI-03Presentation
Innovating Clinical Trial Design in IPF: Lessons from LTI-03
IPFsource ↗
◆Oral PresentationPresentation
Decoding the Disruptions in Natural Biological Processes to Advance Early Intervention in IPF – Unravelling the Molecular Biology of Immune Cells & Inflammation
IPFsource ↗
▲MHRA MilestoneLTI-03Ex-US Regulatory
MHRA authorizes Phase 2 trial of LTI-03 in IPF
idiopathic pulmonary fibrosissource ↗
▼Equity OfferingCorporate
Entered into up to $21 million flexible financing agreements with Yorkville Advisors
▲First Patient DosedLTI-03Trial
First patient dosed in RENEW Phase 2 trial of LTI-03 in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
◆Poster PresentationLTI-03Presentation
Poster presentation on CSD in 3D alveolospheres from IPF and normal donor lung samples at ATS 2025
idiopathic pulmonary fibrosissource ↗
●Preclinical PoCLTI-2355Preclinical
LTI-2355 evaluated in preclinical alveolosphere studies
idiopathic pulmonary fibrosissource ↗
▲Trial InitiationLTI-03Trial
Initiation of RENEW Phase 2 trial of LTI-03 in IPF patients
idiopathic pulmonary fibrosis (IPF)source ↗
◆Oral PresentationPresentation
Rein Therapeutics to present at Citizens Life Sciences Conference 2025
▲Partnership / LicenseCorporate
Collaboration with Qureight for deep-learning platform integration in Phase 2 trial of LTI-03
▲Topline ReadoutLTI-03Clinical Data
Positive topline results from Cohort 2 (5 mg BID) of Phase 1b trial of LTI-03 in IPF
idiopathic pulmonary fibrosis (IPF)source ↗
▲Patent GrantedLTI-03IP / Competition
USPTO granted U.S. Patent No. 12,280,088 and 12,280,089 covering LTI-03 dry powder inhalation formulation and methods of use
interstitial lung disease, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, other inflammatory or fibrotic lung conditionssource ↗
▲PublicationLTI-2355Presentation
Publication in Biomedicines on LTI-2355 immunomodulatory and anti-fibrotic properties
Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F)source ↗
◆Trial InitiationLTI-03Trial
Phase 2 clinical trial of LTI-03 in IPF anticipated to be initiated in first half of 2025
idiopathic pulmonary fibrosissource ↗
▲Topline ReadoutLTI-03Clinical Data
Positive topline results from Phase 1b trial of LTI-03 in IPF (Cohort 2)
idiopathic pulmonary fibrosis (IPF)source ↗
▲Patent GrantedLTI-03IP / Competition
Patents covering novel formulation and administration methods for LTI-03 obtained
▲Partnership / LicenseLTI-03Corporate
Collaboration with Qureight for imaging and data analysis
Past FDA Catalysts and PDUFA Decisions
How RNTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-08 | Inhaled LTI-03 | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$5M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.1x
rNPV / MCap
Top 57%
Micro Cap(rank 375 of 658)
Percentile Rank
Rein Therapeutics, Inc. faces pipeline headwinds (34/100), with $110M risk-adjusted pipeline value, led by LTI-03 in Idiopathic Pulmonary Fibrosis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LTI-03 Small moleculeNCT05954988 | Idiopathic Pulmonary Fibrosis | Phase 2 | COMPLETED | 144 | Sep 25, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every RNTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LTI-03 Fast TrackOrphan | Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | 2026-08-04 | significant reductions in multiple markers of lung scarring and inflammation; LTI-03 was well-tolerated at both doses; no treatment-related discontinuations; mild or moderate side effects; reduced IL-11; reduced TSLP; reduced COL1A1; reduced CXCL7; reduced galectin-7; trend toward reduced levels of surfactant protein D (SP-D)Read More | Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature CommunicationsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| VON RICKENBACH JOSEF HDirector | Buy | 4,500 62,514 held | $1.07 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RNTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RNTX for Q2 2026. | ||||
RNTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RNTX ranks across every disease it competes in
Competitive Position is a premium feature
See how RNTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRNTX News
RNTX▲ +5.4%on this news
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics will present a late-breaking poster on LTI-03 at the ERS 2026 Congress. The poster will discuss a randomized dose escalation study for idiopathic pulmonary fibrosis. LTI-03 is a first-in-class inhaled peptide therapy aimed at inhibiting lung scarring while promoting tissue repair. The RENEW Phase 2 trial is underway to evaluate its safety and efficacy.
Read more →RNTX▲ +5.4%on this newsshared move
Rein Therapeutics to Present at Upcoming September Investor Conferences
Rein Therapeutics will present at two investor conferences in September 2026. CEO Brian Windsor will speak at the Cantor Global Healthcare Conference on September 11 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. The presentations will be accessible via a live webcast on the company's website.
Read more →RNTXRein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received Fast Track Designation from the U.S. FDA for LTI-03, aimed at treating idiopathic pulmonary fibrosis (IPF). This designation underscores the significant unmet medical need in IPF, where existing therapies only slow disease progression. The company is currently enrolling patients in the RENEW Phase 2 trial, with interim data expected in the latter half of 2026.
Read more →RNTXRein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Rein Therapeutics reported its second quarter 2026 financial results, highlighting significant progress in its Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis (IPF). The company surpassed the 25% enrollment milestone and expects to report interim data later this year. Additionally, Rein successfully completed a $57.5 million public offering to support its clinical endeavors. Despite a net loss of $6.4 million, the company remains optimistic about its pipeline and financial position.
Read more →RNTXRein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Rein Therapeutics announced the publication of clinical data for LTI-03 in Nature Communications, demonstrating its safety and efficacy in reducing lung scarring and inflammation in IPF patients. The first-in-human study showed significant improvements in multiple markers after just 14 days of treatment. This publication supports the ongoing Phase 2 RENEW trial, enhancing confidence in LTI-03's potential.
Read more →RNTX▲ +6%on this news
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Rein Therapeutics has announced that its Phase 2 RENEW trial for inhaled LTI-03 is now open for enrollment in five countries, including Germany. The trial aims to evaluate the safety and efficacy of LTI-03 in patients with idiopathic pulmonary fibrosis. Approximately 120 patients will participate, with initial topline data expected in the second half of 2026.
Read more →RNTXRein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Rein Therapeutics has expanded its Phase 2 RENEW trial for LTI-03 into the UK, marking a significant milestone with the first patient randomized. The trial, which targets idiopathic pulmonary fibrosis, has enrolled 16 patients so far and is actively recruiting in the US, Australia, and the UK, with plans to include more countries. The study aims to assess the safety and efficacy of LTI-03, a novel inhaled peptide therapy.
Read more →RNTXRein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Rein Therapeutics has successfully closed a $57.5 million underwritten public offering, which included the full exercise of the over-allotment option. The proceeds will fund the ongoing Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) and support operations until 2028. The offering attracted both new and existing healthcare-focused investors.
Read more →RNTX▼ -24%on this news
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Rein Therapeutics has announced the pricing of a $50 million underwritten public offering of common stock at $1.00 per share. The offering aims to fund the ongoing Phase 2 clinical trial of LTI-03 for idiopathic pulmonary fibrosis and support general corporate purposes. The closing is expected around May 4, 2026, pending customary conditions.
Read more →RNTX▼ -12.1%on this news· ran to -30% by day 3shared move
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has provided an update about its Phase 2 RENEW clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). Currently, 8 patients have been enrolled, with expectations for more as the trial continues to expand across sites in the United States, Australia, and Poland. The study aims to evaluate LTI-03's safety and efficacy in approximately 120 patients, with promising early data suggesting its dual-action capability in treating fibrosis and aiding lung healing. CEO Brian Windsor highlighted the ongoing efforts of clinical teams in progressing the trial.
Read more →RNTXRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
Rein Therapeutics has initiated its Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). The trial, which follows FDA clearance, aims to evaluate the safety and efficacy of LTI-03 in approximately 120 patients across multiple countries. Interim data is expected in the latter half of 2026, marking a significant step in addressing the unmet medical needs of IPF patients.
Read more →RNTXRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has been granted orphan drug designation by the European Medicines Agency for its lead drug candidate LTI-03, aimed at treating idiopathic pulmonary fibrosis (IPF). This designation acknowledges the serious nature of IPF and the need for new therapies. The decision was based on promising preclinical data indicating improved survival and lung function. The designation also provides regulatory incentives to facilitate further development.
Read more →RNTXRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
Rein Therapeutics announced a new preprint detailing the results of a dose-escalation study of LTI-03 in idiopathic pulmonary fibrosis (IPF). The study found that LTI-03 was well tolerated and reduced fibrosis-associated biomarkers while preserving vital lung cells. The findings support LTI-03's potential as a differentiated therapy for IPF, prompting the advancement of the drug into Phase 2 trials.
Read more →RNTX▲ +11.8%on this newsshared move
Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received FDA clearance to resume its Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) after addressing the agency's concerns. The trial, named 'RENEW', will involve approximately 20 U.S. sites and aims to evaluate the drug's safety and efficacy. Initial topline data is anticipated in Q3 2026, marking a significant step forward for the company's development program.
Read more →RNTXRein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics has received European regulatory approval to initiate its Phase 2 'RENEW' trial for LTI-03, targeting idiopathic pulmonary fibrosis. The trial will take place in Germany and Poland, following prior clearance from the UK. The study aims to evaluate the safety and efficacy of LTI-03, which has a dual mechanism to combat fibrosis and support lung tissue regeneration.
Read more →RNTXRein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
Rein Therapeutics announced the publication of new data on its drug candidate LTI-03, demonstrating anti-fibrotic activity in lung tissue from IPF patients. The findings support the ongoing Phase 2 RENEW trial, which aims to evaluate LTI-03's safety and efficacy. The urgent need for effective treatments in IPF is emphasized by the disease's high mortality rate and limited current options.
Read more →RNTXRein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic
Rein Therapeutics has received U.K. regulatory approval to commence its Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF). This trial, named "RENEW," will assess the safety and tolerability of LTI-03 in up to 120 patients worldwide. The company's lead drug candidate aims to directly target lung fibrosis and has the potential to significantly improve patient outcomes. Initial data from the trial is expected in 2026, with patient recruitment beginning shortly in the U.K.
Read more →RNTXRein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics will present at the IPF Summit 2025, showcasing insights into idiopathic pulmonary fibrosis (IPF) treatment. Chief Scientific Officer Cory Hogaboam will discuss biological processes in IPF, while CEO Brian Windsor will share lessons from clinical trials. The summit aims to advance understanding and treatment of IPF.
Read more →RNTXRein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing
Rein Therapeutics has entered into financing agreements with Yorkville Advisors, potentially granting access to $21 million. This funding will primarily support the RENEW Phase 2 trial for LTI-03, aimed at treating idiopathic pulmonary fibrosis, alongside other corporate needs. The company emphasizes its commitment to developing innovative therapies for orphan diseases.
Read more →RNTXRein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Rein Therapeutics announced the adjournment of its 2025 annual meeting due to a lack of quorum. The meeting will reconvene on July 23, 2025, allowing stockholders more time to vote on proposals. The company continues to encourage participation from stockholders who have not yet voted.
Read more →About Rein Therapeutics, Inc.
Headquarters12407 N. MOPAC EXPY., AUSTIN, TX, 78758
BIOPHARMAWATCH ELITE PLUS
Trade the next RNTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime